If you've started a GLP-1 medication and stopped, or you're worried you'd be wasting money by starting, here's something worth knowing: quitting is the norm, not the exception. And if you're a woman navigating your 40s or 50s, you already know the extra layer no one talks about: a metabolism that changed the rules on you, and a weight-loss industry that talks at you instead of to you.
The three reasons are below. The third one is the one almost nobody checks before signing up.
Those numbers surprise people, because the medications themselves work. In clinical trials of FDA-approved brand-name semaglutide and tirzepatide (compounded versions were not studied), the medications produced average weight reductions of about 15% (semaglutide 2.4 mg)[2] to 21% (tirzepatide 15 mg)[3] over 68 to 72 weeks, alongside diet and exercise changes. The science isn't the weak link.
So why do most people stop? In that study, moderate or severe gastrointestinal side effects were linked to a higher chance of stopping, and higher household income was linked to a lower chance[1], which points to two familiar pressures: cost and unmanaged side effects. And here's the part almost nobody talks about: both of those are usually program problems, not medication problems. They're determined by which program you sign up with, often before your first dose ships.
1. The price shock that arrives at month two
Many programs advertise an attractive first-month price, then step up sharply, or the advertised price quietly excludes the consultation fee, the shipping, or the dose you'll actually need by month three. When the real monthly number lands, people quit. Not because they wanted to stop treatment, but because the bill stopped making sense next to groceries, kids, and everything else a real budget carries. This was never about discipline. It's arithmetic.
Takeaway: the real price is the month-six price, not the month-one price.
2. Side effects with nobody to call
Most GLP-1 side effects (nausea, digestive discomfort) are manageable with dose adjustments and clinical guidance, and they typically ease as your body adapts. But that requires a program where a licensed clinician actually responds when it's 9pm, the nausea is real, and you need an answer, not a support ticket.
This is where programs differ enormously. Some build clinical follow-through into the product: scheduled check-ins, care-team messaging, dose changes handled proactively. Others are closer to a prescription vending machine: you get your shipment, and you're on your own. The data suggests that people in unsupported programs quietly quit when side effects appear, while people with responsive clinical support adjust the dose and continue.
Takeaway: side effects are manageable, but only in a program where someone actually answers.
3. The wrong medication, and no way to switch
Semaglutide and tirzepatide behave differently from person to person. Some people respond better to one than the other; some need a different dose curve than the standard schedule. Programs that lock you into a single medication leave you with two options when it isn't working: push through, or quit.
A smaller group of programs lets you switch medications under clinical supervision without starting over. In the retention data, that flexibility matters: it converts "this isn't working, I'm done" into "let's adjust."
Takeaway: pick a program that can adjust, so a rough start is not the end of your treatment.
Every program here holds current LegitScript certification and uses licensed US clinicians before it earns a listing. We rate on price that holds, real clinical support, and medication flexibility. We may earn a commission if you choose a program through our links; it never changes the ranking.
We scored all 22 certified programs against these three failure points. One kept winning.
Every program we review is LegitScript-certified and doctor-supervised; that's the entry bar. But when we rated them specifically on the three things that make people quit (sustainable pricing, responsive clinical support, and medication flexibility), one program earned our Editor's Pick, and it isn't close on the third point: switching medications under supervision is built into how it works.
★ Editor's Pick: 4.9/5
What happens after you click
The process is simpler than most people expect, and it happens entirely from your couch: no waiting rooms, no scale in a hallway, no explaining yourself at a front desk. You answer a short health questionnaire (about 5 minutes), a licensed clinician reviews it and confirms whether GLP-1 treatment is appropriate for you, and if approved, your medication ships to your door. If the clinician determines it isn't right for you, you don't pay for medication. That medical gate is exactly what separates legitimate programs from the rest.
And if week three gets rough, or the first medication isn't the right fit, you message the care team and adjust. That's the whole point: you're not signing up for a shipment, you're signing up for supervised treatment that can bend instead of break.
Ready to be in the group that stays on track?
Answer the health questionnaire and a licensed clinician takes it from there. About 5 minutes, no obligation, and the reader pricing is applied automatically.
Start your free Omzo evaluation →Three questions people ask before clicking
Not sure Omzo fits you? Compare all 22 certified programs with our 60-second quiz →